Charmsaz Sara, Scott Andrew M, Boyd Andrew W
Leukaemia Foundation Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, Australia; Department of Medicine, University of Queensland, Brisbane, Australia; Department of Surgery, Royal College of Surgeons, Dublin, Ireland.
Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.
Exp Hematol. 2017 Oct;54:31-39. doi: 10.1016/j.exphem.2017.07.003. Epub 2017 Jul 24.
The use of monoclonal antibodies (mAbs) and molecules derived from them has achieved considerable attention and success in recent years, establishing this mode of therapy as an important therapeutic strategy in many cancers, in particular hematological tumors. mAbs recognize cell surface antigens expressed on target cells and mediate their function through various mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or immune system modulation. The efficacy of mAb therapy can be improved when they are conjugated to a highly potent payloads, including cytotoxic drugs and radiolabeled isotopes. The Eph family of proteins has received considerable attention in recent years as therapeutic targets for treatment of both solid and hematological cancers. High expression of Eph receptors on cancer cells compared with low expression levels in normal adult tissues makes them an attractive candidate for cancer immunotherapy. In this review, we detail the modes of action of antibody-based therapies with a focus on the Eph family of proteins as potential targets for therapy in hematological malignancies.
近年来，单克隆抗体（mAb）及其衍生分子受到了广泛关注并取得了显著成功，使这种治疗方式成为许多癌症（尤其是血液肿瘤）的重要治疗策略。单克隆抗体识别靶细胞上表达的细胞表面抗原，并通过各种机制介导其功能，如抗体依赖性细胞毒性、补体依赖性细胞毒性或免疫系统调节。当单克隆抗体与高效载荷（包括细胞毒性药物和放射性标记同位素）偶联时，其治疗效果可以得到提高。近年来，Eph蛋白家族作为实体癌和血液癌治疗的靶点受到了广泛关注。与正常成人组织中的低表达水平相比，癌细胞上Eph受体的高表达使其成为癌症免疫治疗的一个有吸引力的候选靶点。在这篇综述中，我们详细阐述了基于抗体的治疗作用模式，重点关注Eph蛋白家族作为血液系统恶性肿瘤治疗的潜在靶点。
